TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03737968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: durvalumab + tremelimumab
Description: Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
Study: NCT03637192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low altitude: 470m above sea level
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low altitude: 470m above sea level
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study: NCT02376036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD010
Description: MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine, inactivated

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Hepatitis A vaccine, inactivated
Study: NCT03350737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Description: Standard treadmill exercise session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical rehabilitation
Description: Standard treadmill exercise session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin i.v.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% i.v.
Study: NCT02129933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence endoscopy platform
Description: A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
Study: NCT04480593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazilian Green Propolis Extract (EPP-AF)
Description: Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazilian Green Propolis Extract (EPP-AF)
Description: Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
Study: NCT02526680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrCam
Description: The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
Study: NCT03092557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of local pleural strain
Description: For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
Study: NCT03637192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Säntis; 2500m above sea Level
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT01839877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIA DEBIRI + systemic FOLFOX
Study: NCT03709810

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Marketed Denture Adhesive (Super Poligrip Max Seal)
Description: The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
Study: NCT03593070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Grief Management Intervention-Video
Description: The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
Study: NCT03709810

Intervention type: OTHER
Group type: OTHER
Intervention: No Adhesive
Description: No adhesive will be applied.
Study: NCT04709991

Intervention type: PROCEDURE
Intervention: Endovascular procedure
Description: Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.

Intervention type: PROCEDURE
Intervention: Endovascular procedure
Description: Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
Study: NCT00323622

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection in the deltoid muscle
Study: NCT06630429

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples
Study: NCT00323622

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix®
Description: IM injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix®
Description: IM injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: IM injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: IM injection in the deltoid muscle
Study: NCT03023982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: All blocks will be done under ultrasound
Study: NCT00323622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Study: NCT03023982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy
Description: The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: standard pain control with opioids
Study: NCT00067717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance healing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Distance healing
Study: NCT03023982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids
Description: standard pain control with opioids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: standard pain control with NSAIDs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: standard pain control with NSAIDs
Study: NCT02488759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Study: NCT03914287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Myofascial release
Description: The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
Study: NCT06628544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Description: BCG vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Description: BCG vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Description: BCG vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Description: BCG vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin is administered on the day 0
Description: Metformin is administered on the day 0

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin is administered on the day 9
Description: Metformin is administered on the day 9
Study: NCT02367170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure
Description: Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation \>92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure
Description: Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation \>92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
Study: NCT06628544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin is administered on the day 85
Description: Metformin is administered on the day 85
Study: NCT06631651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachioradialis release
Description: During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Brachioradialis not released
Description: During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed.
Study: NCT02675374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine (Polaramine®) injection
Description: 5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 5 minutes before CPB, patients will receive 2 ml of normal saline
Study: NCT04701424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX Closed-loop
Description: The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Daily Insulin Injections (Control)
Description: Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
Study: NCT04067193

Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.

Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.

Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
Study: NCT00294892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbamazepine and nevirapine
Description: Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nevirapine
Description: Nevirapine 200mg is taken prior to delivery during labor.
Study: NCT03003364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XCEL-UMC-BETA
Description: Intrathecal allogeneic cell therapy in a blinded syringe
Study: NCT00323622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Study: NCT01333579

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
Study: NCT04824976

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry
Description: freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched powder maltodextrin twice daily = 60kcal
Study: NCT04529915

Intervention type: DIAGNOSTIC_TEST
Intervention: Exosome sampling
Description: * Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Exosome sampling
Description: * Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis
Study: NCT03929510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06651600
Description: Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06651600 IV
Description: IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Oral solution 200mg
Study: NCT03445520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Coaching Group
Description: Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
Study: NCT04087174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Patients will receive multiple oral dose of capivasertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Patients will receive multiple oral dose of capivasertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Patients will receive multiple oral dose of capivasertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Patients will receive multiple oral dose of capivasertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Patients will receive multiple oral dose of capivasertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Patients will receive multiple oral dose of capivasertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive 160 mg oral dose of enzalutamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive 160 mg oral dose of enzalutamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive 160 mg oral dose of enzalutamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive 160 mg oral dose of enzalutamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Patients will receive 1000 mg oral dose of abiraterone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Patients will receive 1000 mg oral dose of abiraterone.
Study: NCT00747461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoSpray Ablation
Description: Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
Study: NCT00839852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study: NCT02838446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)
Study: NCT01222624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX™

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX™

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX™
Study: NCT03561116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XAN
Description: Daily intake of a sachet containing 12 mg of XAN
Study: NCT02243592

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Undergo sequencing and SNP analysis
Study: NCT03561116

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of a sachet containing excipient
Study: NCT02002273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Switching level of suction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Switching level of suction